Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo

Acta Biomaterialia

Volumn 8, Issue 11, 2012, Pages 4092-4100

  Yau, Jonathan W ^a,c   Stafford, Alan R ^a,c   Liao, Peng ^a,c   Fredenburgh, James C ^a,c   Roberts, Robin ^a,c   Brash, John L ^a   Weitz, Jeffrey I ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Catheter thrombosis; Contact activation; Corn trypsin inhibitor; Factor xii; Fondaparinux; Surface modification

Indexed keywords

BLOOD VESSELS; CATHETERS; CHEMICAL ACTIVATION; COATINGS; ENZYME INHIBITION; SURFACE TREATMENT;

AUTOACTIVATION; CATHETER THROMBOSE; CONTACT ACTIVATION; CORN TRYPSIN INHIBITORS; FACTOR XII; FONDAPARINUX; IN-VITRO; PROPERTY; SURFACE-MODIFICATION; VITRO AND IN VIVO;

DISEASES;

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; CORN TRYPSIN INHIBITOR; FIBRINOGEN; FONDAPARINUX; OVALBUMIN; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; BIOMATERIAL; POLYSACCHARIDE; TRYPSIN INHIBITOR, ZEA MAYS; VEGETABLE PROTEIN; WATER;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CATHETER OCCLUSION; CATHETER THROMBOSIS; CONTROLLED STUDY; GUIDING CATHETER; IN VITRO STUDY; MAIZE; MALE; MATERIAL COATING; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BINDING; PROTHROMBIN TIME; X RAY PHOTOELECTRON SPECTROSCOPY; ANIMAL; BLOOD CLOTTING; CATHETER; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; PERCUTANEOUS CORONARY INTERVENTION; RABBIT; SURFACE PROPERTY; THROMBOSIS;

ORYCTOLAGUS CUNICULUS; ZEA MAYS;

ADSORPTION; ANIMALS; BLOOD COAGULATION; CATHETERS; COATED MATERIALS, BIOCOMPATIBLE; FACTOR XII; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PHOTOELECTRON SPECTROSCOPY; PLANT PROTEINS; POLYSACCHARIDES; PROTEIN BINDING; RABBITS; SURFACE PROPERTIES; THROMBOSIS; WATER;

EID: 84873973841     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2012.07.019     Document Type: Article

References (48)

1. Chan MY, Weitz JI, Merhi Y, Harrington RA, Becker RC. Catheter thrombosis and percutaneous coronary intervention: Fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. J Thromb Thrombolysis 2009;28(3):366-80.
2. Montalescot G, Walenga JM. Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants. Clin Appl Thromb Hemost 2009;15(2):183-96.
3. White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372(9638):570-84.
4. Amlani S, Nadarajah T, Afzal R, Pal-Sayal R, Eikelboom JW, Natarajan MK. Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. J Thromb Thrombolysis 2010;30(4):434-40.
5. Happe LE, Rao SV, Horblyuk R, Franklin M, Lunacsek OE, Menditto L. Consequences of major bleeding in hospitalized patients with non-ST segment elevation acute coronary syndromes receiving injectable anticoagulants. Curr Med Res Opin 2009;25(2):413-20.
6. Lindsey JB et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. JACC Cardiovasc Interv 2009;2(11):1074-82.
7. Manoukian SV, Voeltz MD, Eikelboom J. Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk. Clin Cardiol 2007;30(10 Suppl. 2):24-34.
8. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 Suppl):141S-59S.
9. Yusuf S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354(14):1464-76.
10. Yusuf S et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA 2006;295(13):1519-30.
11. Mehta SR et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007;50(18):1742-51. (Pubitemid 47600591)
12. Kannemeier C et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007;104(15):6388-93. (Pubitemid 47186104)
13. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006;103(4):903-8. (Pubitemid 43212194)
14. Tans G, Griffin JH. Properties of sulfatides in factor-XII-dependent contact activation. Blood 1982;59(1):69-75. (Pubitemid 12162347)
15. Sanchez J, Elgue G, Larsson R, Nilsson B, Olsson P. Surface-Adsorbed fibrinogen and fibrin may activate the contact activation system. Thromb Res 2008;122(2):257-63.
16. Zhuo R, Siedlecki CA, Vogler EA. Autoactivation of blood factor XII at hydrophilic and hydrophobic surfaces. Biomaterials 2006;27(24):4325-32. (Pubitemid 43674176)
17. Altieri P et al. Acute coronary syndromes do not promote prolonged in vivo FXII-dependent prothrombotic activity. Thromb Res 2005;115(1-2):65-72. (Pubitemid 39572757)
18. de la Cadena RA, Wachtfogel YT, Colman RW. Contact activation pathway: Inflammation and coagulation. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott; 1994. p. 219-40.
19. Yau JW, Stafford AR, Fredenburgh JC, Brash JL, Weitz JI. Immobilization of corn trypsin inhibitor reduces the in vitro procoagulant properties of catheters. J Thromb Haemost 2009;7(Suppl. 2):PP-MO-428.
20. Yau JW, Stafford AR, Liao P, Fredenburgh JC, Roberts R, Weitz JI. Mechanism of catheter thrombosis: comparisonof the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood 2011;118(25):6667-74.
21. Hojima Y, Pierce JV, Pisano JJ. Hageman factor fragment inhibitor in corn seeds: purification and characterization. Thromb Res 1980;20(2):149-62. (Pubitemid 11174769)
22. Alibeik S, Zhu S, Yau JW, Weitz JI, Brash JL. Surface modification with polyethylene glycol-corn trypsin inhibitor conjugate to inhibit the contact factor pathway on blood-contacting surfaces. Acta Biomater 2011;7(12): 4177-86.
23. Alibeik S, Zhu S, Yau JW, Weitz JI, Brash JL. Modification of polyurethane with polyethylene glycol-corn trypsin inhibitor for inhibition of factor XIIa in blood contact. J Biomater Sci Polym Ed, in press. http://dx.doi.org/10.1163/092050611x603250.
24. Alibeik S, Zhu S, Yau JW, Weitz JI, Brash JL. Dual surface modification with PEG and corn trypsin inhibitor: Effect of PEG:CTI ratio on protein resistance and anticoagulant properties. J Biomed Mater Res A 2012;100(4):856-62.
25. Anderson JA, Fredenburgh JC, Stafford AR, Guo YS, Hirsh J, Ghazarossian V, et al. Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase. J Biol Chem 2001;276(13):9755-61.
26. Ross CD, inventor. Engineering Resources Group I, assignee. Guide catheter. United States patent 7306585. 6 A.D. Apr 6.
27. Kretz CA, Cuddy KK, Stafford AR, Fredenburgh JC, Roberts R, Weitz JI. HD1, a thrombin-And prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions. Thromb Haemost 2010;103(1):83-93.
28. Fredenburgh JC, Stafford AR, Weitz JI. Conformational changes in thrombin when complexed by serpins. J Biol Chem 2001;276(48):44828-34.
29. Du YJ, Brash JL, McClung G, Berry LR, Klement P, Chan AK. Protein adsorption on polyurethane catheters modified with a novel antithrombin-heparin covalent complex. J Biomed Mater Res A 2007;80(1):216-25. (Pubitemid 44913349)
30. Wang P, Tan KL, Kang ET. Surface modification of poly(tetrafluoroethylene) films via grafting of poly(ethylene glycol) for reduction in protein adsorption. J Biomater Sci Polym Ed 2000;11(2):169-86. (Pubitemid 30107730)
31. Archambault JG, Brash JL. Protein resistant polyurethane surfaces by chemical grafting of PEO: Amino-terminated PEO as grafting reagent. Colloids Surf B Biointerfaces 2004;39(1-2):9-16. (Pubitemid 39473347)
32. Chen H, Zhang Z, Chen Y, Brook MA, Sheardown H. Protein repellant silicone surfaces by covalent immobilization of poly(ethylene oxide). Biomaterials 2005;26(15):2391-9. (Pubitemid 39600692)
33. Sousa SR, Moradas-Ferreira P, Saramago B, Melo LV, Barbosa MA. Human serum albumin adsorption on TiO2 from single protein solutions and from plasma. Langmuir 2004;20(22):9745-54.
34. Vogler EA. Water and the acute biological response to surfaces. J Biomater Sci Polym Ed 1999;10(10):1015-45.
35. Kang IK, Kwon BK, Lee JH, Lee HB. Immobilization of proteins on poly(methyl methacrylate) films. Biomaterials 1993;14(10):787-92. (Pubitemid 23247507)
36. de Queiroz AA, Barrak ER, Gil HA, Higa OZ. Surface studies of albumin immobilized onto PE and PVC films. J Biomater Sci Polym Ed 1997;8(9): 667-81. (Pubitemid 27526781)
37. Vogler EA, Graper JC, Harper GR, Sugg HW, Lander LM, Brittain WJ. Contact activation of the plasma coagulation cascade. I. Procoagulant surface chemistry and energy. J Biomed Mater Res 1995;29(8):1005-16.
38. Du YJ, Klement P, Berry LR, Tressel P, Chan AK. In vivo rabbit acute model tests of polyurethane catheters coated with a novel antithrombin-heparin covalent complex. Thromb Haemost 2005;94(2):366-72. (Pubitemid 41122492)
39. Chen H, Chen Y, Sheardown H, Brook MA. Immobilization of heparin on a silicone surface through a heterobifunctional PEG spacer. Biomaterials 2005;26(35):7418-24. (Pubitemid 41133593)
40. Chen H, Zhang Y, Li D, Hu X, Wang L, McClung WG, et al. Surfaces having dual fibrinolytic and protein resistant properties by immobilization of lysine on polyurethane through a PEG spacer. J Biomed Mater Res A 2009;90(3): 940-6.
41. Nilsson PH, Engberg AE, Back J, Faxalv L, Lindahl TL, Nilsson B, et al. The creation of an antithrombotic surface by apyrase immobilization. Biomaterials 2010;31(16):4484-91.
42. Chen H, Brook MA, Chen Y, Sheardown H. Surface properties of PEO-silicone composites: reducing protein adsorption. J Biomater Sci Polym Ed 2005;16(4):531-48. (Pubitemid 41348807)
43. Park K, Shim HS, Dewanjee MK, Eigler NL. In vitro and in vivo studies of PEOgrafted blood-contacting cardiovascular prostheses. J Biomater Sci Polym Ed 2000;11(11):1121-34. (Pubitemid 32208300)
44. Marois Y et al. An albumin-coated polyester arterial graft: In vivo assessment of biocompatibility and healing characteristics. Biomaterials 1996;17(1):3-14. (Pubitemid 126755186)
45. Alibeik S, Zhu S, Brash JL. Surface modification with PEG and hirudin for protein resistance and thrombin neutralization in blood contact. Colloids Surf B Biointerfaces 2010;81(2):389-96.
46. Maitz MF, Sperling C, Werner C. Immobilization of the irreversible thrombin inhibitor D-Phe-Pro-Arg-chloromethylketone: A concept for hemocompatible surfaces? J Biomed Mater Res A 2010;94(3):905-12.
47. Colman RW, Scott CF, Pixley RA, de la Cadena RA. Effect of heparin on the inhibition of the contact system enzymes. Ann NY Acad Sci 1989;556: 95-103. (Pubitemid 19199303)
48. Vogler EA, Siedlecki CA. Contact activation of blood-plasma coagulation. Biomaterials 2009;30(10):1857-69.